AbbVie reportedly in talks to buy biotech for $10.9B eczema drug

INSUFFICIENT_FACTS: Who is involved? (target company name, any named executives, deal advisors), What number matters? (drug development stage, clinical trial phase, market size data, comparative valuations), What changed versus prior expectations? (prior guidance on M&A spending, portfolio strategy, consensus expectations), Why does it matter for investors? (specific revenue exposure from Rinvoq or other dermatology assets, patent cliff timing, competitive positioning versus named rivals), What should readers watch next? (announcement timing, due diligence completion date, regulatory filing deadline, shareholder vote date)